Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Dazodalibep in Healthy Adults
NCT02151110Phase 1Completed
- Sponsor
- MedImmune
- Start
- May 2014
- Primary completion
- May 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dazodalibep in autoimmune diseases (8 arms), sponsored by MedImmune. Primary endpoint: Treatment Emergent Adverse Events. Started May 2014; status: completed.
02
Drugs
dazodalibep
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT02151110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02151110.